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The identification of certain members of the large superfamily of ATP binding cassette
transport proteins such as MDR1-P-glycoprotein and the multidrug resistance protein
MRP1 as ATP-dependent drug efflux pumps has been a major contribution in our
understanding of the multidrug resistance phenotype of cancer cells. Importantly, both
transport proteins that exhibit only low structural homology have a very different
substrate specificity but confer resistance to a similar spectrum of natural product
chemotherapeutic drugs. In contrast to the drug transporter MDR1, MRP1 mainly
transports anionic Phase II-conjugates. In addition MRP1-mediated drug resistance is
highly dependent on high intracellular glutathione levels which may be linked to the
apparent physiological involvement of MRP1 in glutathione-related cellular processes.
This review summarizes the current knowledge about functional aspects of MRP1 and
its 5 recently cloned homologues MRP2 - MRP6 and discuss their substrate
specificities and cellular localisation with emphasis on drug resistance.
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Introduction
Development of drug resistance during chemotherapy is a major obstacle in the
successful treatment of human cancers. In vitro studies with tumour cell lines as model
systems have demonstrated that exposure to a single drug often results in cross-
resistance to many other structurally and functionally unrelated compounds. This
phenomenon is known as multidrug resistance (MDR). Among the several identified
drug resistance mechanisms, the ATP-binding cassette (ABC) transport proteins are of
particular interest.
Human ABC transporters were originally associated with drug resistance and cystic
fibrosis.1 The identification of novel members of the ABC family revealed that they
are also involved in several human diseases including Tangier disease, Stargardt
disease,  adrenoleukodystrophy and a group of liver disorders known as progressive
familial intrahepatic cholestasis 2 (see also http://www.med.rug.nl/mdl/humanabc.htm).
The discovery of the ABC transporter MDR1-P-glycoprotein (MDR1) opened a new
research area in understanding the human drug resistance phenotype.3 Overexpression
of this 170-kDa transmembrane protein confers resistance to a wide spectrum of
natural product drugs by an ATP-dependent extrusion of these compounds resulting in
decreased intracellular levels (reviewed in ref. 4). For several years, MDR1 was the
only ABC transport protein associated with drug resistance. However, reports
describing drug resistant cell lines without MDR1-overexpression indicated the
presence of other MDR-conferring proteins.5,6 This led to the identification of a second
drug resistance-related ABC transporter, the multidrug resistance protein (MRP),7
further designated as MRP1 (symbol ABCC1). MDR1 and MRP1 confer resistance to
a similar, although not identical, group of anticancer drugs. However, these proteins
share less than 20% amino acid identity. This suggested that MDR1 and MRP1 confer
drug resistance by different mechanisms. The cloning of the MRP1 homologues MRP2
(ABCC2) 8 and, more recently, MRP3 (ABCC3), MRP4 (ABCC4), MRP5 (ABCC5) and
MRP6 (ABCC6) 9,10 defined a new subfamily of ABC transporters with potential
involvement in drug resistance. This review summarises the current knowledge on the
MRP family with emphasis on its relationship to drug resistance.
MRP1
Mechanisms of MRP1-mediated drug resistance
Sequestration
The relationship between overexpression of MRP1 and drug resistance has been firmly
established (for review see refs. 11,12). Overexpression of MRP1 leads to an increased
ATP-dependent drug efflux resulting in decreased intracellular concentrations.13
However, the level of MRP1 overexpression often does not correlate with the amount
of drug exported from the cells and sometimes MRP1-overexpressing cells do not even
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show an increased drug efflux.7,14,15 Compared to the sensitive counterparts, certain
MRP1-overexpressing, drug-resistant cells show different drug distributions, with
accumulation of the fluorescent drugs doxorubicin or daunorubicin into intracellular
vesicular structures.16-19 A direct link between MRP1 and intracellular doxorubicin
distribution was demonstrated using the MRP1 inhibitor MK571.20 In sensitive cells
doxorubicin accumulated into the nucleus, while in the resistant MRP1-overexpressing
counterparts doxorubicin showed an exclusively cytoplasmic distribution. Treatment of
the resistant cells with MK571 resulted in a redistribution of doxorubicin into the
nucleus.19 This suggested that MRP1 is active in preventing entry of drugs into the
nucleus where several anticancer drugs exert their cytotoxic activity. Besides its
localisation to the plasma membrane, MRP1 is also found in intracellular membranes
from secretory vesicles putatively derived from the Golgi apparatus.21,22 It was shown
in drug-resistant cells that the MRP1 substrate dinitrophenyl-glutathione (DNP-GS)
was sequestrated in these vesicles.22 These results demonstrate that MRP1 is
intracellularly active and that sequestration of drugs in intracellular vesicles provides
another mechanism, besides drug efflux, for MRP1-mediated drug resistance (Figure
1).
Transport
Until recently, the mechanism by which MRP1 could transport chemotherapeutic drugs
was not clear. The initial idea was that MRP1, similar to MDR1, could be a
translocator for unmodified drugs. Indeed, if these anticancer drugs are anionic
compounds, they are transported by MRP1 without further modification as described
for the antifolate methotrexate.23 However, unmodified basic anticancer drugs per se
are not transported by MRP1.24-26
Based on its transport function for GSH-, glucuronic acid- and sulphate
conjugates,24 it was proposed that MRP1 might confer drug resistance by export of
drug conjugates. MRP1 is able to transport glutathione S-conjugates (GS S-conjugates)
of the alkylating agents chlorambucil and melphalan,27 although MRP1 is not known to
confer resistance to these drugs. On the other hand, many chemotherapeutic drugs to
which MRP1 confers resistance are not substrates for GSH-, glucuronic acid- or
sulphate conjugation.14 GSH however does play an important role. Experiments with
membrane vesicles from MRP1-overexpressing cells demonstrated that MRP1 is a
transporter for the unmodified anticancer drugs vincristine and daunorubicin, but only
in the presence of physiological amounts of GSH.25,26 These results extend the earlier
observations that GSH is a critical factor in MRP1-mediated drug resistance (Figure
1).28,29
The molecular mechanism of drug transport by MRP1 is still puzzling. It is not
dependent on the reducing capacity of GSH, since other reducing agents such as
dithiothreitol, 2-mercaptoethanol and L-cysteine do not stimulate MRP1-mediated
vincristine transport.25 In addition, the GSH-derived dipeptides cysteinylglycine and γ-
glutamylcysteine do not stimulate vincristine transport by MRP1 either.30
Consequently, MRP1-mediated vincristine transport requires an intact GSH molecule.
Studies with embryonic stem cells from Mrp1 +/+ mice showed increased GSH efflux
after etoposide exposure in contrast to the same cells from Mrp1 -/- knockout mice.31
Furthermore, vincristine stimulates GSH transport into membrane vesicles from
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MRP1-overexpressing cells.30 These findings strongly indicated that MRP1-mediated
transport of vinca alkaloids occurs via a co-transport mechanism with GSH. This
suggests that GSH itself is also transported by MRP1. Previous work supports this
idea. A direct interaction of GSH with MRP1 has been proposed,32 MRP1-
overexpressing cells showed increased GSH release 28,29 and Mrp1 -/- mice showed
increased GSH levels in their tissues.31 However, when membrane vesicles from
MRP1-overexpressing cells were used, transport of GSH itself could not be
observed.30  An explanation for this discrepancy might be the presence of endogenous
MRP1 substrates inside the cell inducing an increased GSH release via the postulated
co-transport mechanism. In experiments with membrane vesicles these endogenous
substrates are not present. Thus, MRP1-mediated GSH transport seems dependent on
the presence of other (hydrophobic) compounds. These compounds are not necessarily
MRP1 substrates as was shown for the calcium channel blocker verapamil.33
Alternatively, according to the transport capacity for oxidized glutathione (GSSG) it
may be that two GSH molecules are transported by MRP1. Low affinity ATP-
dependent transport of GSH per se was measured in yeast vacuolar membrane vesicles
containing the MRP1-homologue yeast cadmium factor 1 (YCF1).34 Thus GSH itself
may be a MRP1 substrate but, due to high Km values, ATP-dependent transport can not
be measured in vitro. Moreover, compared to yeast vacuolar membrane vesicles,
mammalian membrane vesicles are less rigid and are variably orientated making
reliable measurements of MRP1-mediated GSH transport extremely difficult.
MRP1-mediated daunorubicin transport also requires GSH 26 and is also dependent
on an intact GSH molecule (Renes et al. unpublished observations). However, in
contrast to vinca alkaloids, efflux of daunorubicin from MRP1-overexpressing cells is
not accompanied by an increased release of GSH.29 Thus either the mechanism of
MRP1-mediated daunorubicin transport is different compared to vincristine transport,
or these data are not comparable because of different cell lines and experimental
conditions. The elucidation of the molecular mechanism of MRP1-mediated
daunorubicin transport requires further research.
Transport of drug metabolites
Intracellular metabolism of the anticancer drugs cyclophosphamide and bleomycin
results in formation of toxic metabolites such as base propanals and the α,β-
unsaturated aldehyde acrolein.35 Doxorubicin is known to generate oxidative stress and
subsequently formation of a lipid peroxidation product, the α,β-unsaturated aldehyde
4-hydroxynonenal (4HNE).36,37 The main detoxification mechanism for toxic
aldehydes is conjugation to GSH, the so-called phase II metabolism.35 This is
illustrated by transfection with a gene encoding a glutathione S-transferase (GST)
isoenzyme with high affinity for 4HNE resulting in resistance to doxorubicin.38
Accumulation of the endogenously formed GS S-conjugates, however, may cause
product inhibition of the GST’s and decrease in detoxification capacity.39 Therefore,
extrusion from the cell is required. According to its substrate specificity, the GS S-
conjugates formed after drug administration are potential MRP1 substrates. Indeed it
was shown that the GS S-conjugate of 4HNE (GS-4HNE) is a high-affinity substrate
for MRP1 and that MRP1 protects against 4HNE toxicity.40 MRP1 may thus play a
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role in drug resistance by export of GS S-conjugates of drug metabolites (Figure 1).











Figure 1. Model of MRP1-mediated drug resistance. After entering the cell MRP1 prevents the drug
reaching its target by (1) sequestration into intracellular vesicles or (2) export from the cell with or
without the aid of GSH. Drug metabolites can be detoxified by conjugation to GSH followed by MRP1-
mediated transport out of the cell (3).
Regulation of MRP1-expression
A conclusive mechanism for drug-induced MRP1 expression can not be provided yet,
but there is evidence that MRP1 expression is triggered by oxidative stress. In human
colon cancer cells MRP1 gene expression is induced by tumour necrosis factor α
(TNF).41 A similar effect was observed when rats were treated with lipopolysaccharide
(LPS) resulting in increased liver Mrp1 expression. TNF is believed to be one of the
main causes of LPS-induced effects on transporter gene expression in hepatocytes.42 In
addition, it was demonstrated recently in mouse T helper cells that from all cytokines
tested only TNF in combination with interleukin-2 (IL-2) induced Mrp1 expression.43
One of the mechanisms by which TNF exert its intracellular effects is the formation of
reactive oxygen species (ROS).44 Compounds known to generate ROS induce
expression of the genes encoding MRP1 and γ-glutamylcysteine synthetase (γGCS)
and provide a direct link between ROS and MRP1 induction.45 γGCS is the rate-
limiting enzyme in GSH synthesis and GSH plays an important role in the protection
against oxidative-stress metabolites.39 Increased GSH levels generated by γGCS
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transfection reduced MRP1 expression.45 In addition, compounds detoxified by GSH
such as heavy metals and 3-[4-amino-2-methyl-5-pyrimidinylmethyl]-1-(2-
chloroethyl)-nitrosourea (ACNU) have the capacity to induce expression of
MRP1.46,47,48 These results suggest that GSH is a critical factor in MRP1 regulation.
However, GSH depletion by the γGCS inhibitor buthionine sulfoximine (BSO) did not
induce MRP1 expression. Explanation for this might be a BSO-resistant GSH pool
present in mitochondria and nucleus. This pool is sensitive to anticancer drugs.45 We
propose here a model for drug-induced MRP1 expression. Low concentrations of
anticancer drugs can be detoxified by MRP1 with the aid of cytoplasmic GSH.
Increased drug concentrations will first deplete cytoplasmic GSH, followed by
depletion of the BSO-resistant pool. This may drop GSH levels below a critical value
resulting in an alteration of the cellular redox state and action of transcription factors,
which may be the trigger for induction of MRP1 (and γGCS) expression. Although the
promoter region of MRP1 contains an antioxidant responsive element,49 a direct link
between oxidative stress sensitive transcription factors and MRP1 induction has not
been demonstrated yet. Another transcription factor, Sp1, seems to play a role in
regulation of MRP1 expression.49 MRP1 promoter activity is decreased when Sp1
binding sites are deleted or mutated,50 while overexpression of Sp1 protein induces
MRP1 promoter activity.51 Wild type p53 (wt p53), a protein mainly involved in cell
cycle control,52 forms complexes with Sp1 53 and these may inhibit MRP1 promoter
activity. Indeed, wt p53 represses MRP1 expression.51,54 Mutant p53, the most
frequently found alteration in human malignancies,55 is also able to bind Sp1 but this
might result in a complex with reduced repression activity as it was shown that
overexpression of mutant p53 induces MRP1 expression,54 (Renes et al., submitted).
Questions remain about the basal transcription factors that are responsible for
oxidative stress-mediated induction of MRP1.
How does MRP1 function as transport protein?
Which are the regions in MRP1 that determine its function, where are the substrate
binding sites and what is the mechanism by which MRP1 exerts its transport activity?
Eukaryotic ABC transporters are commonly composed of two hydrophobic
membrane-spanning domains (MSDs) and two cytoplasmic nucleotide-binding
domains (NBDs), organised as NH2-MSD1-NBD1-MSD2-NBD2-COOH.1 In this
respect, MRP1 is different because it contains an extra N-terminal MSD with five
membrane-spanning segments. Topology studies predicted a secondary MRP1
structure as: NH2-MSD1-MSD2-NBD1-MSD3-NBD2-COOH.56 The extra N-terminal
MSD is characteristic for certain members of the MRP family (MRP1, MRP2, MRP3
and MRP6) (Figure 2) and other strongly related ABC transporters such as the
sulfonylurea receptor (SUR), YCF1,57 the MRP1-homologue in the nematode
Caenorhabditis elegans 58 and the MRP1-homologue found in the plant Arabidopsis
thaliana (AtMRP1).59 All ABC proteins containing a third MSD are more closely
related to MRP1 and to each other than to other members of the ABC superfamily. The
function of this N-terminal part of MRP1 has been examined and it appears that










Figure 2. Membrane topology models of the MRP family. MSD: membrane spanning domain; NBD:
nucleotide binding domain.
Removal of the first membrane-spanning segment resulted in impaired leukotriene
C4 (LTC4) transport.60 However, when the entire MSD1 was deleted, the transport
activity of MRP1 was hardly decreased and MRP1 still correctly localized to the
basolateral membranes of transfected MDCKII cells.61 It appears that MSD1 is not a
determinant domain for MRP1 function and cellular trafficking. However, removal of
the linker region between MSD1 and MSD2 strongly decreased LTC4 transport,
suggesting that this region is a critical domain for the transport activity of MRP1.61
The potential importance of the first membrane-spanning segment of MSD1 for MRP1
function remains to be elucidated.
Transport studies showed that LTC4 transport is inhibited by the hydrophilic
substrates GSSG and nonyl-GS 62 and by hydrophobic anticancer drugs. This
inhibition was further increased when GSH was included.25 In addition, photoaffinity
labelling of MRP1 by LTC4 is inhibited by 17β-glucuronosyl estradiol (E2 17βG).63
These results suggest that different MRP1 substrates have identical or overlapping
binding sites. However, different parts of MRP1 seem to determine the transport
process. In contrast to human MRP1, murine Mrp1 does not confer resistance to
doxorubicin and is not a transporter for E2 17βG.64 A hybrid protein containing the
murine N-terminal part and the human C-terminal part restored doxorubicin resistance
and the capacity to transport E2 17βG. However, this was not observed using a hybrid
protein containing the human N-terminal and mouse C-terminal parts.65 These results
demonstrate the importance of the C-terminal part of MRP1 for doxorubicin resistance
and E2 17βG transport. However, the efficiency of LTC4 transport seems to be the
same for wild type proteins and hybrid proteins.65 Thus, MRP1 appears to contain
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different determinants for transport of E2 17βG and LTC4, although they seem to have
identical or overlapping binding sites.
Although LTC4, GSH and anticancer drugs interact with MRP1 directly, 63,32
specific binding sites have not yet been identified. The development of monoclonal
antibodies directed against specific epitopes of MRP1 is an important step towards
elucidating specific substrate-binding sites.66 It is unlikely that specific regions in the
MRP1 protein are exclusively responsible for transport of specific substrates. The
monoclonal antibody QCRL-3, which recognises a conformation-dependent epitope in
the NBD1, inhibits transport of the hydrophilic substrates LTC4,25,26 and E2 17βG 67
but also of the hydrophobic substrates vincristine and daunorubicin.26,30 In addition,
transport of LTC4 and vincristine is inhibited by the monoclonal antibody QCRL-4
which recognises an epitope in NBD2.66,30 Inhibition by these antibodies is not caused
by steric effects or by inhibition of ATP-binding.66 These results indicate that NBD1
and NBD2 either contain a specific substrate-binding site (hydrophilic or hydrophobic)
or that these two NBDs are otherwise involved in the transport process. Thus, it
appears that the transport function of MRP1 depends on an interplay between different
regions.
MRP1 requires ATP-hydrolysis for its transport function 62,24-26 and it has been
suggested that the ATPase activity of the NBDs provides the energy for the transport
process.68 Three different experimental systems have been used to study the ATPase
activity of MRP1 and all three gave different results.68-70 One study, using
reconstituted MRP1, showed that anticancer drugs in the absence of GSH and
anticancer drugs to which MRP1 does not confer resistance stimulate the ATPase
activity of MRP1. Furthermore it was shown that GSH stimulated drug-induced
ATPase activity.68 This was not observed in the other studies. In contrast to Mao et
al.,69 it was demonstrated in membrane vesicles from MRP1-overexpressing cells that
GSH itself is a strong stimulator of MRP1 ATPase activity.70 These discrepancies may
be explained by differences in the lipid environment of MRP1, since small changes in
lipid composition strongly affect ATPase activity of MDR1.71 However, consensus
was reached about the stimulatory activities of LTC4. Remarkably, an artificial GS S-
conjugate of daunorubicin (WP811), but not unconjugated daunorubicin, stimulated
MRP1 ATPase activity.70 This indicates that the anionic part of conjugated MRP1
substrates may play a key role in the transport process. The same may be true for
anticancer drugs that require GSH for their transport.30,26 The stimulation of the
ATPase activity by GSH alone supports this idea.70
Recently, the involvement of the two NBDs from MRP1 in the coupling between
ATP hydrolysis and transport activity was further elucidated.72-74 Interaction of ATP
with MRP1 was studied by photoaffinity labelling and vanadate-induced trapping
experiments using 32P-labeled 8-azido-ATP. Binding of azido-ATP was exclusively
found at NBD1, while trapping of azido-ADP was predominantly observed at NBD2.
This is in agreement with the previously proposed separate ATP- and ADP-binding
sites on MRP1.75 Trapping of ADP was stimulated by LTC4, GSSG, GSH and
etoposide and synergistically by etoposide with either GSH or GSSG.72-74 Why
etoposide per se stimulates trapping while other drugs are not able to do this, remains
to be elucidated. The two NBDs show co-operativity in the binding and trapping of the
nucleotide:  trapping of ADP at NBD2 requires the presence of a functional NBD1 72,74
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and binding of ATP at NBD1 was reduced when NBD2 was mutated.74 In addition,
ADP (putatively bound to NBD2) stimulated specific binding of ATP at NBD1,
suggesting an allosteric interaction between the two NBD’s.74 Thus, although both
NBDs seem to be functionally non-equivalent, they are interdependent. Mutation of
the highly conserved lysine residues in the Walker A or B motifs from either NBD
resulted in impaired binding and trapping of the nucleotide and reduced LTC4
transport.72,74 Remarkably, mutations in NBD2 were more effective in reduction of
LTC4 transport than mutations in NBD1.72,74 This may indicate a more critical role for
NBD2-mediated ATP hydrolysis for substrate transport. A model was proposed
describing the coupling between ATP binding and hydrolysis and transport activity.74
In summary, the molecular mechanism of MRP1-mediated transport is far from
elucidated and requires integration of knowledge on substrate binding, ATPase activity
and translocation processes.
Physiological function of MRP1
MRP1 was first characterised as a transporter for anionic conjugates, preferentially GS
S-conjugates.62,25,24 GSH is ubiquitously present in all cells of the human body and
plays an important role in detoxification of ROS, electrophiles and oxyanions either by
reduction or conjugation.39 GS S-conjugates are substrates with highest affinity for
MRP1 and the affinity increases with the length of the alkyl chain.76,25 Based on its
ubiquitous expression 77 and its substrate specificity, it was proposed that extrusion of
endogenously formed GSH-dependent detoxification products is the physiological
function of MRP1.78 Indeed, MRP1 is a transporter for LTC4,62,25 the glutathione
conjugate of prostaglandin A2 (GS-PGA2),79,80 GSSG 81 and GS-4HNE.40 LTC4 and
PGA2 are involved in inflammation and cell cycle arrest,82,83 while GSSG and GS-
4HNE are detoxification products generated under conditions of a changed redox
state.39,84 A role of MRP1 in immune responses was recently proposed based on the
induction of its murine orthologue upon activation of T-helper 1 cells.43 MRP1-
mediated transport of GSSG and GS-4HNE suggests that MRP1 functions as part of
the cellular defence system against oxidative stress.81,40 Thus, extrusion of the above-
mentioned metabolites by MRP1 may be required to retain the response against
inflammatory stimuli and to prevent cellular damage.
The generation of Mrp1 -/- knockout mice has significantly contributed to the
understanding of the physiological role of MRP1. Mice lacking Mrp1 show a poor
response to inflammation induced by arachidonic acid, probably due to impaired
export of LTC4 form LTC4-secreting cells.85 In addition, Mrp1 plays a role in the
protection of testicular tubules, tongue, cheek, and the urinary collecting duct against
etoposide-induced damage.86 Recently, the presence of Mrp1 in mouse and rat choroid
plexus (CP) was shown.87-89 It is located on the basolateral site of CP epithelial cells.87
Mrp1 expression in rat CP was higher than in the lung, a tissue with a relative high
basal Mrp1 expression.88 Functionality of Mrp1 was strongly suggested by a rapid
elimination of E2 17βG from the CP 88 and by MK571-mediated inhibition of
translocation of 99mTc-sestamibi through CP epithelial cells.87 Comparison of double
(Mdr1a/Mdr1b) and triple (Mdr1a/Mdr1b/Mrp1) knockout mice clearly demonstrated
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that Mrp1 eliminates the anticancer drug etoposide from the CP.89 Thus Mrp1 appears
to function also as part of the blood-cerebrospinal fluid barrier by preventing drug
entry into the brain.
MRP2
The natural Mrp2 mutant TR- 90 and Eisai hyperbilirubinemic (EHBR) 91 rats have
significantly contributed to the understanding of the transport characteristics of human
MRP2. Mutant rats lacking the canalicular multispecific organic anion transporter
(cMOAT, designated further as MRP2) have a hyperbilirubinemic phenotype and
impaired secretion of bilirubin glucuronides, sulphated bile salts, GS S-conjugates and
GSH into the bile.92 These rats serve as model for Dubin-Johnson disease as this
disorder is caused by mutations in the MRP2 gene.93 The transport properties of MRP2
could be characterised more precisely after cloning of the rat and human Mrp2/MRP2
cDNAs.94,8 The substrate specificity of MRP2 is largely similar to MRP1 (Table 1) but
the kinetic properties of both transporters differ (for review see ref. 76). Also, various
unmodified organic anions such as indomethacin, sulphinpyrazone and probenecid act
differently on MRP1- and MRP2-mediated N-ethylmaleimide-glutathione transport
and on the ATPase activity of the two proteins.95 This suggests that MRP1 and MRP2
differ in their transport of specific organic compounds.
In normal tissues, MRP2 is expressed in liver, small intestine and kidney 9 where the
protein is localized to apical membranes.93,96 An overview of the localisation of all
MRP proteins in polarised cells is given in Figure 3.




MRP1 MRP3 MRP4 MRP5 MRP6
Figure 3. Localisation of MRP family members in polarized cells.
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Transport studies showed that rat Mrp2 may function as a transporter for DNP-GS
into the intestinal lumen.97 ATP-dependent transport of DNP-GS and E2 17βG was
detected into brush border membrane vesicles from Caco-2 cells overexpressing MRP2
mRNA.98 In kidney proximal tubules, active transport mechanisms exist for anionic
drugs such as diuretics, penicillins and cephalosporins and also for other unmodified
anionic compounds such as para-aminohippurate (PAH) and anionic conjugates of
several metabolites.99,100 The involvement of MRP2 in this process was proposed
because of its apical localisation in kidney tubules and its capacity to transport anionic
compounds.101,95 This was confirmed by experiments showing MRP2 to be a
transporter for PAH and for the nephrotoxic mycotoxin ochratoxin A.102 Furthermore,
transport of fluorescein-methotrexate into kidney proximal tubules from killifish was
shown to be Mrp2 dependent.103
Based on its localisation and substrate specificity, it is proposed that the
physiological function of MRP2 is transport of amphiphilic organic anions and
xenobiotics into bile and into the lumen of excretory organs.
The similarity of substrate specificity between MRP1 and MRP2 suggests that
MRP2 also can confer drug resistance. Overexpression of MRP2 mRNA was found in
several drug-resistant cell lines, but only a correlation for cisplatin resistance could be
observed.9 Previous studies showed an increased ATP-dependent extrusion of GSH-
cisplatin complexes from cells overexpressing a GS-X pump 104 but this appeared to be
MRP1.105 MRP1 overexpression is not associated with cisplatin resistance 13 and cells
selected with cisplatin do not show increased MRP1 expression.9,106
Direct evidence that MRP2 is associated with drug resistance was provided by
stable transfected cell lines.23,107-110 Transfection of MRP2 constructs into non-
polarised cells often resulted in low protein expression and/or trapping of the
transporter into endosomal compartments. Because of the strict apical localisation of
MRP2, polarised cells were the preferred system for transfection.111 MRP2
transfectants showed resistance to vincristine, etoposide, cisplatin, doxorubicin,
epirubicin and methotrexate 108,109,23 with decreased accumulation of vincristine,
cisplatin and methotrexate.109,23 MRP2 only causes resistance to short-term exposure
of methotrexate. Long-term exposure to methotrexate results in polyglutamylation of
the drug and this metabolite is not a substrate of MRP2.109
Transport of anticancer drugs was demonstrated using membrane vesicles from
MRP2 transfectants 23 and from Spodoptera frugiperda (Sf9) insect cells
overexpressing rabbit or human Mrp2/MRP2.112,95 Methotrexate is transported by
MRP2 in its native form 23,95 while vinblastine transport required GSH with a half-
maximum stimulation at about 2 mM.112  Recently it was shown that vinblastine
induces MRP2-mediated GSH transport.113 In this respect, the functions of MRP2 and
MRP1 are similar. Taken together, methotrexate per se is transported by MRP1 and
MRP2 and both proteins show similar behaviour in the transport of vinca alkaloids.
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MRP3
Expression of MRP3 was first detected in liver, intestine and adrenal gland.9 Cloning
of the human and rat MRP3 cDNAs 114,115 made it possible to study localisation and
transport properties (Table 1). MRP3 is found on (baso)lateral membranes of
intrahepatic bile-duct epithelial cells (cholangiocytes), hepatocytes surrounding the
portal tracts and polarised Madin-Darby canine kidney (MDCK) cells transfected with
a MRP3 construct.116,117  Furthermore, it is suggested that MRP3 is also present on
basolateral membranes of enterocytes.118 Under normal conditions, MRP3 staining is
hardly detectable in the liver, however, strong MRP3 staining was observed in
hepatocytes from MRP2-deficient Dubin-Johnson patients.117 A similar effect was seen
in EHBR rats also lacking Mrp2 and in bile-duct ligated (BDL) Sprague-Dawley wild-
type rats.115 This suggests that MRP3 expression is induced under these conditions. In
fact, MRP2 and MRP3 expression was inversely correlated under conditions of
reduced MRP2 expression.119 Furthermore, MRP3 mRNA is induced by bilirubin.
However, MRP3 protein expression was not increased suggesting that this depends on
other factors.120
The increased expression of MRP3 in Dubin-Johnson patients, its induction during
BDL and its substrate specificity suggests that MRP3 may function as an overload
system to (partly) compensate for decreased MRP2 expression and to protect
hepatocytes from toxic bile salts during conditions of cholestasis. Furthermore, its
localisation on basolateral membranes of cholangiocytes 116 and enterocytes 118
suggests that MRP3 may also be involved in the recirculation of bile salts from these
cells into the blood. The function of MRP3 in the adrenal gland is unclear but it may
contribute to the excretion of hydrophilic steroid hormone conjugates.
Within the MRP family MRP3 shows highest homology to MRP1 (58% amino acid
identity) and MRP2 (49% amino acid identity).111 Rat Mrp3 prefers glucuronide-
conjugates as substrates and is a low-affinity transporter for GS S-conjugates, in
contrast to Mrp1 and Mrp2.121 For biliary secretion of bile salts at least two
transporters are involved. The bile salt export protein (Bsep) transports unconjugated
bile salts such as taurocholate, cholate and glycocholate,122 while sulphated bile salts
as taurochenodeoxycholeate-3-sulphate and taurolithocholate-3-sulphate are Mrp2
substrates.123,124 Remarkably, Mrp3 transports both conjugated and unconjugated bile
salts across the basolateral membrane.118 Thus, although the substrate specificities of
MRP3 and MRP2 are overlapping, there are clear differences.
While the homology between MRP3 and MRP1/MRP2 is high, the drug resistance
profile conferred by MRP3 is different. Of the many cytostatic drugs tested, MRP3
conferred resistance only to etoposide, teniposide, vincristine and methotrexate.116,125
Rat Mrp3 is a transporter for native methotrexate 121 but, similar to MRP2, MRP3-
mediated resistance to methotrexate was restricted to short-term exposure of this
drug.116
In contrast to MRP1- and MRP2-overexpressing cells, GSH secretion in MRP3
transfectants was not increased. GSH is important in MRP1- and MRP2-mediated drug
transport and it was speculated that the limited resistance pattern conferred by MRP3
could be due to low expression levels and/or a low affinity for GSH. In this respect it
is interesting to know how MRP3 is involved in resistance against etoposide and
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vincristine since MRP1, and probably MRP2, require GSH for transporting these
anticancer drugs.
MRP4 - 6
Overexpression of MRP4, MRP5 and MRP6 has not been detected in drug-resistant
cell lines suggesting that their role in ‘classical’ drug resistance is limited.9,10 MRP4
and MRP5 differ from MRP1, MRP2, MRP3 and MRP6 in that they lack the N-
terminal MSD 111 (Figure 2). Whether this is determinant for their function remains to
be established. Overexpression of MRP4, but not MRP1, MRP2 and MRP3, was found
in human T-lymphoid CEM cells resistant to nucleoside monophosphate analogues
which are currently used as components of anti-retroviral therapy against HIV
infections.126 MRP4 overexpression caused an increased efflux of 9-(2-phosphonyl-
methoxyethyl)adenine (PMEA) and azidothymidine monophosphate (AZTMP)
resulting in decreased anti-viral efficacy (Table 1). Prolonged exposure of CEM cells
to PMEA showed gene amplification of MRP4 with a corresponding increase in
protein expression and drug efflux.126 These results suggest that induction of MRP4
expression during anti-viral therapy may cause a failure in inhibition of HIV
replication in host cells.
Expression of MRP5 was detected in almost every tissue of the human body, with
relative high expression in skeletal muscle and brain.9 Cells transfected with a MRP5
construct were tested for resistance against many anticancer drugs and other cytotoxic
agents but showed only resistance to cadmium chloride and potassium antimonyl
tartrate.127 In another study, MRP5-transfected cells showed increased resistance to
thio-purines and also PMEA which was caused by an increased efflux.128 In addition,
these cells showed increased efflux of GSH and GS S-conjugates to the basolateral
compartment which was inhibited by inhibitors of organic anion transport. It was
demonstrated that MRP5 localized to basolateral membranes.128 Thus MRP5 is routed
to the basolateral membrane and serves as a transporter for organic anions and certain
types of drugs (Table 1).
Recently, MRP5 was identified as a transporter for cyclic guanosine
monophosphate  (cGMP) (high affinity) and cyclic adenosine monophosphate (cAMP)
(low affinity).129 The second messengers cGMP and cAMP exert their function in
cellular signal transduction in several physiological processes such as smooth muscle
relaxation, inhibition of platelet aggregation and neuronal communication, mostly
initiated by nitric oxide.130,131 The drug silfenadil (Viagra) which inhibits
intracellular cGMP degradation has been shown to reduce MRP5-mediated cGMP
transport.129 Thus, as transporter for cAMP and cGMP, MRP5 may function in the
regulation of their intracellular levels and may play a role in their extracellular actions.
The development of the mrp5-/- knockout mice will provide an excellent model to
study further the transport properties and the physiological role of MRP5.111
MRP6 does not contribute to drug resistance and its overexpression in drug resistant
cells is associated with co-amplification of MRP1. This may be related to the
localisation of MRP6 next to MRP1 on the same chromosome.10 The previously
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identified “ARA” gene 132 is identical to the 3’ end of MRP6 and “ARA”-associated
resistance may be explained by co-amplification of MRP1.
Rat and human mrp6/MRP6 are mainly expressed in normal liver and kidney.10,133
In the liver, Mrp6 is predominantly found on the lateral plasma membranes of
hepatocytes.133 In Mrp2-deficient or cholestatic rats, Mrp6 expression is not induced,
in contrast to Mrp3.115,133 This suggests that Mrp6 is constitutively expressed in the
liver. The function of Mrp6 is not clear. It is not a transporter for Mrp1/Mrp2
substrates and the only Mrp6 substrate identified thus far is BQ123, a
cyclopentapeptide antagonist of the endothelin receptor.133 Because of its constitutive
expression in the liver and its capacity to transport BQ123, Mrp6 was suggested to
function as a transporter for small peptides involved in cellular signalling and/or
autocrine or paracrine regulation of hepatocellular functions.133
The physiological importance of Mrp6/MRP6 expression in the liver remains to be
further elucidated. It may be associated with pseudoxanthoma elasticum (PXE), a
systemic connective tissue disorder affecting the elastic tissue network in the body,
since mutations in the MRP6 gene are associated with this disease.134 Although PXE is
a disorder affecting the whole body, MRP6 was found only in liver and kidney from
PXE patients. Thus the primary defect of this disease may reside in the liver and/or
kidney. How MRP6 is associated with PXE is presently unclear.
Conclusions
The discovery of the MRP family has broadened our understanding of the mechanisms
responsible for drug resistance in malignant cells. On the other hand MRP family
members, individually or in concert, may have important physiological functions in
protecting the body against xenobiotics and in cellular homeostasis. The association of
mutations in MRP2 and MRP6 genes in clinical disorders as Dubin-Johnson and PXE
is an example of the indispensability of these transporters. Although there is no
conclusive evidence for the function of either of these transporters in clinical drug
resistance, the presence of at least six MRP members in the human body may have
clinical implications for drug treatment. The implications stem not only from MRP-
mediated drug resistance, but also from drug-mediated interference in the
physiological function of individual MRP family members. Therefore, it is important
to elucidate the contribution of each of the MRP transporters in drug resistance and
normal metabolism in the human body.
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Table 1. Substrate specificity of the MRP family.
Substrate Resistance Transport/efflux References
MRP1 (human, recombinant)
Glutathione disulfide (GSSG) + 81
Glutathione (GSH) + 29
GSH + vincristine + 30
GSH + verapamil + 33
Glutathione S-conjugates
Leukotriene C4 + 135,62
Leukotriene D4 + 135,24
Leukotriene E4 + 135,24
N-Acetyl-leukotriene E4 + 24







S-glutathionyl ethacrynic acid + 136
S-glutathionyl N-ethylmaleimide + 61
S-glutathionyl 4-hydroxynonenal + 40
S-glutathionyl aflatoxin B1 + 137
Monochloro-monoglutathionyl chlorambucil + 27
Monohydroxy-monoglutathionyl
chlorambucil + 27
Bisglutathionyl chlorambucil + 27
Monochloro-monoglutathionyl melphalan + 27
Monohydroxy-monoglutathionyl melphalan + 27
Glucuronide conjugates
Monoglucuronosyl bilirubin + 138
Bisglucuronosyl bilirubin + 138
17β-Glucuronosyl estradiol + 24,63
6α-Glucuronosyl hyodeoxycholate + 24
Glucuronosyl etoposide + 24
Sulphate conjugate








Vincristine + GSH + 25,26
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Vinblastine + 13
Methotrexate + + 23
7-ethyl-10-hydroxy-campothecin (SN-38) + + 140
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-
carbonyloxycampothecin (CPT-11) + + 140
Heavy metals
Sodium arsenite + 13,29
Sodium arsenate + 13
Potassium antimony tartrate + 13










Glutathione (GSH) + 145,113
GSH + vinblastine + 113
GSH + sulphinpyrazone + 113
Glutathione S-conjugates
Leukotriene C4 + 108,109
S-glutathionyl 2,4,-dinitrobenzene + 107,108
S-glutathionyl ethacrynic acid + 107
S-glutathionyl prostaglandin A1 + 107
S-glutathionyl N-ethylmaleimide + 95
Glucuronide conjugates
Monoglucuronosyl bilirubin + 146
Bisglucuronosyl bilirubin + 146











7-ethyl-10-hydroxy-campothecin (SN-38) + + 110
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-
carbonyloxycampothecin (CPT-11) + + 110
Anions
p-Aminohippurate + 102
Ochratoxin A + 102
Sulphinpyrazone + 113
Mrp2 (rodent, recombinant)
Leukotriene C4 + 147,148
S-glutathionyl 2,4,-dinitrobenzene + 147
Monoglucuronosyl bilirubin + 146
Bisglucuronosyl bilirubin + 146
17β-Glucuronosyl estradiol + 108,148
Vinblastine + GSH + 112
BQ123 + 133
MRP3 (human, recombinant)
S-glutathionyl 2,4,-dinitrobenzene + 116
Methotrexate + 116, 125




Leukotriene C4 + 121
S-glutathionyl 2,4,-dinitrobenzene + 121
17β-Glucuronosyl estradiol + 121
E3040-glucuronide + 121
Cholyl taurine + 118
Cholyl glycine + 118
3α-Sulfatolithocholyl taurine + 118
Methotrexate + 121
MRP4 (human)




Azidothymidine (AZT) + 126
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Azidothymidine monophosphate + 126
(AZTMP)
2’,3’-dideoxy-3’-thiacytidine (3TC) + 126
2’,3’-didehydro-3’-deoxythymidine (d4T)a) + 126
MRP5 (human, recombinant)
Glutathione (GSH) + 128
S-glutathionyl 2,4,-dinitrobenzene + 128
Fluorochrome + 127, 128
Cadmium chloride + 127
Potassium antimonyl tartrate + 127
6-Mercaptopurine + + 128
Thioguanine + 128
9-(2-phosphonyl-methoxyethyl)adenine + + 128
(PMEA)
5-hydroxypy-2-carboxaldehyde-
thiosemicarbazone (5-HP) + 128
Cyclic AMP + 129
Cyclic GMP + 129
Mrp6 (rodent, recombinant)
BQ123 + 133
For MRP1, MRP2 and MRP3 this table is modified from König et al.76 Putative Mrp2 substrates
derived from TR- and EHBR rats are described in König et al.76 and Suzuki and Sugiyama.92
a)
 Cytotoxicity of d4T was not determined but MRP4 caused decreased antiviral activity of this drug.
Abbreviations used: GSH, glutathione (reduced); GSSG, glutathione disulfide (oxidized glutathione);
Fluo-3, 1-[2-amino-5-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)]-2-(2’-amino-5’-methylphen-
oxy)-ethane-N,N,N’,N’-tetraacetic acid penta ammonium salt; C6-NBD, 6(N-(7-nitrobenz-2-oxa-
1,3,diazol-4-yl); BQ123, endothelin antagonist, cyclic pentapeptide (cyclo [D-Trp-D-Asp-L-Pro-D-Val-
L-Leu]; E3040-glucuronide, 6-hydroxy-5,7-dimethyl-2-methylamino-4(3-pyridylmethyl)benzothiazole),




1. Higgins CF. ABC transporters: from microorganism to man. Annu. Rev. Cell Biol. 1992; 8: 67-
113.
2. Klein I, Sarkadi B, and Varadi A. An inventory of the human ABC proteins. Biochim. Biophys.
Acta 1999; 1461: 237-262.
3. Juliano RL and Ling V. A surface glycoprotein modulating drug permeability in chinese
hamster ovary cell mutants. Biochim. Biophys. Acta 1976; 455: 152-162.
4. Ueda K, Yoshida A, and Amachi T. Recent progress in P-glycoprotein research. Anticancer
Drug Des. 1999; 14: 115-121.
5. Mirski SE, Gerlach JH, and Cole SPC. Multidrug resistance in a human small cell lung cancer
cell line selected in adriamycin. Cancer Res. 1987; 47: 2594-2598.
6. McGrath T and Center MS. Adriamycin resistance in HL60 cells in the absence of detectable
P- glycoprotein. Biochem. Biophys. Res. Commun. 1987; 145: 1171-1176.
7. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz
EU, Duncan AM, and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant
human lung cancer cell line. Science 1992; 258: 1650-1654.
8. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K,
Okamura K, Akiyama S, and Kuwano M. A human canalicular multispecific organic anion
transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cells with
decreased drug accumulation. Cancer Res. 1996; 56: 4124-4129.
9. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, and Borst P.
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the
multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res.
1997; 57: 3537-3547.
10. Kool M, van der Linden M, de Haas M, Baas F, and Borst P. Expression of human MRP6, a
homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer
Res. 1999; 59: 175-182.
11. Loe DW, Deeley RG, and Cole SPC. Biology of the multidrug resistance-associated protein,
MRP. Eur. J. Cancer 1996; 32A: 945-957.
12. Hipfner DR, Deeley RG, and Cole SPC. Structural, mechanistic and clinical aspects of MRP1.
Biochim. Biophys. Acta 1999; 1461: 359-376.
13. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG.
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cancer Res. 1994; 54: 5902-5910.
14. O'Brien ML and Tew KD. Glutathione and related enzymes in multidrug resistance. Eur. J.
Cancer 1996; 32A: 967-978.
15. Versantvoort CHM, Withoff S, Broxterman HJ, Kuiper CM, Scheper RJ, Mulder NH, and de
Vries EGE. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines
with increasing adriamycin resistance. Int. J. Cancer 1995; 61: 375-380.
16. Slapak CA, Mizunuma N, and Kufe DW. Expression of the multidrug resistance associated
protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994;
84: 3113-3121.
17. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, and Kruh GD.
Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug
resistance associated with increased drug efflux and altered intracellular drug distribution.
Cancer Res. 1995; 55: 5342-5347.
18. Coley HM, Amos WB, Twentyman PR, and Workman P. Examination by laser scanning
confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in
parent and multidrug resistant cell lines. Br. J. Cancer 1993; 67: 1316-1323.
Functions of the MRP-family
25
19. Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Müller M, Groen HJ, Smit
EF, and de Vries EGE. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in
doxorubicin-resistant tumor cell lines. Int. J. Cancer 1997; 73: 362-366.
20. Gekeler V, Ise W, Sanders HK, Ulrich WR, and Beck J. The leukotriene LTD4 receptor
antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem.
Biophys. Res. Commun. 1995; 208: 345-352.
21. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Scheper RJ, and Zaman GJ.
Immunochemical detection of the multidrug resistance-associated protein MRP in human
multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994; 54: 4557-4563.
22. Van Luyn MJ, Müller M, Renes J, Meijer C, Scheper RJ, Nienhuis EF, Mulder NH, Jansen
PLM, and de Vries EGE. Transport of glutathione conjugates into secretory vesicles is
mediated by the multidrug-resistance protein 1. Int. J. Cancer 1998; 76: 55-62.
23. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ,
Borst P, Pinedo HM, and Jansen G. Antifolate resistance mediated by the multidrug resistance
proteins MRP1 and MRP2.  Cancer Res. 1999; 59: 2532-2535.
24. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and Keppler D. Transport of
glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export
pump. Cancer Res. 1996; 56: 988-994.
25. Loe DW, Almquist KC, Deeley RG, and Cole SPC. Multidrug resistance protein (MRP)-
mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. J.
Biol. Chem. 1996; 271: 9675-9682.
26. Renes J, de Vries EGE, Nienhuis EF, Jansen PLM, and Müller M. ATP- and glutathione-
dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br.
J. Pharmacol. 1999; 126: 681-688.
27. Barnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, König J, Lehmann WD, and
Keppler D. Multidrug resistance protein-mediated transport of chlorambucil and melphalan
conjugated to glutathione.  Br. J. Cancer 1998; 77: 201-209.
28. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, and Twentyman PR. Regulation by
glutathione of drug transport in multidrug-resistant human lung tumour cell lines
overexpressing multidrug resistance-associated protein. Br. J. Cancer 1995; 72: 82-89.
29. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma CC, Oude Elferink
RPJ, Baas F, and Borst P. Role of glutathione in the export of compounds from cells by the
multidrug-associated protein. Proc. Natl. Acad. Sci. USA 1995; 92: 7690-7694.
30. Loe DW, Deeley RG, and Cole SPC. Characterization of vincristine transport by the M(r)
190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione.
Cancer Res. 1998; 58: 5130-5136.
31. Rappa G, Lorico A, Flavell RA, and Sartorelli AC. Evidence that the multidrug resistance
protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer
Res. 1997; 57: 5232-5237.
32. Taguchi Y, Yoshida A, Takada Y, Komano T, and Ueda K. Anti-cancer drugs and glutathione
stimulate vanadate-induced trapping of nucleotide on multidrug resistance-associated protein
(MRP). FEBS Lett. 1997; 401: 11-14.
33. Loe DW, Deeley RG, and Cole SPC. Verapamil stimulates glutathione transport by the 190-
kDa multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 2000; 293: 530-538.
34. Rebbeor JF, Connolly GC, Dumont ME, and Ballatori N. ATP-dependent transport of reduced
glutathione on YCF1, the yeast orthologue of mammalian multidrug resistance associated
proteins. J. Biol. Chem. 1998; 273: 33449-33454.
35. Berhane K, Widersten M, Engstrom A, Kozarich JW, and Mannervik B. Detoxication of base
propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid




36. Gille L and Nohl H. Analyses of the molecular mechanism of adriamycin-induced
cardiotoxicity. Free Rad. Biol. Med. 1997; 23: 775-782.
37. Ollinger K and Brunmark A. Effect of different oxygen pressures and N,N'-diphenyl-p-
phenylenediamine on Adriamycin toxicity to cultured neonatal rat heart myocytes. Biochem.
Pharmacol. 1994; 48: 1707-1715.
38. He NG, Singhal SS, Srivastava SK, Zimniak P, Awasthi YC, and Awasthi S. Transfection of a
4-hydroxynonenal metabolizing glutathione S-transferase isozyme, mouse GSTA4-4, confers
doxorubicin resistance to Chinese hamster ovary cells. Arch. Biochem. Biophys. 1996; 333:
214-220.
39. Wang W and Ballatori N. Endogenous glutathione conjugates: occurrence and biological
functions. Pharmacol. Rev. 1998; 50: 335-356.
40. Renes J, de Vries EGE, Hooiveld GJEJ, Krikken I, Jansen PLM, and Müller M. The multidrug
resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-
hydroxynonenal. Biochem. J. 2000; 350: 555-561.
41. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, and Shoemaker RH. Tumor
necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and
MRP. J. Natl. Cancer Inst. 1997; 89: 807-813.
42. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, and Müller M.
Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the
organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver.
Hepatology 1998; 28: 1637-1644.
43. Prechtl S, Roellinghoff M, Scheper RJ, Cole SPC, Deeley RG, and Lohoff M. The multidrug
resistance protein 1: a functionally important activation marker for murine Th1 cells. J.
Immunol. 2000; 164: 754-761.
44. Goossens V, Grooten J, De Vos K, and Fiers W. Direct evidence for tumor necrosis factor-
induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity.
Proc. Natl. Acad. Sci. USA 1995; 92: 8115-8119.
45. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy T, Ishikawa T, and Kuo MT. Expression
of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthase genes is
regulated by oxidative stress.  J. Biol. Chem. 1998; 273: 31075-31085.
46. Ishikawa T, Bao J-J, Yamane Y, Akimaru K, Frindlich K, Wright CD, and Kuo MT.
Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy
metals in human leukemia cells. J. Biol. Chem. 1996; 271: 14981-14988.
47. Gomi A, Shinoda S, Masuzawa T, Ishikawa T, and Kuo MT. Transient induction of the
MRP/GS-X pump and gamma-glutamylcysteine synthase by 1-(4-amino-2-methyl-5-
pyridinyl)methyl-3-(2-chloroethyl)-3-nitrosourea in human glioma cells. Cancer Res. 1997; 57:
5292-5299.
48. Vernhet L, Courtois A, Allain N, Payen L, Anger JP, Guillouzo A, and Fardel O.
Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-
selected tumor cells. FEBS Lett. 1999; 443: 321-325.
49. Zhu Q and Center MS. Cloning and sequence analysis of the promoter region of the MRP gene
of HL60 cells isolated for resistance to adriamycin. Cancer Res. 1994; 54: 4488-4492.
50. Zhu Q and Center MS. Evidence that SP1 modulates transcriptional activity of the multidrug
resistance-associated protein gene. DNA Cell Biol. 1996; 15: 105-111.
51. Wang Q and Beck WT. Transcriptional suppression of multidrug resistance-associated protein
(MRP) gene expression by wild-type p53. Cancer Res. 1998; 58: 5762-5769.
52. Levine A. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
53. Borellini F and Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during
granulocyte/macrophage colony-stimulating factor-dependent proliferation in human
erythroleukemia cell line TF-1. J. Biol. Chem. 1993; 268: 7923-7928.
Functions of the MRP-family
27
54. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, and Hait WN. Regulation of
expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J.
Clin. Invest. 2000; 105: 1261-1267.
55. Hollstein M, Sidransky D, Vogelstein B, and Harris CC. p53 mutations in human cancers.
Science 1991; 253: 49-53.
56. Hipfner DR, Almquist KC, Leslie EM, Gerlach JH, Grant CE, Deeley RG, and Cole SPC.
Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site
mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. 1997; 272: 23623-23630.
57. Tusnady GE, Bakos E, Varadi A, and Sarkadi B. Membrane topology distinguishes a
subfamily of the ATP-binding cassette (ABC) transporters. FEBS Lett. 1997; 402: 1-3.
58. Broeks A, Gerrard B, Allikmets R, Dean M, and Plasterk RHA. Homologues of the human
multidrug resistance genes MRP and Pgp contribute to heavy metal resistance in the soil
nematode Caenorhabditis elegans. EMBO J. 1996; 15: 6132-6142.
59. Lu YP, Li ZS, and Rea PA. AtMRP1 gene of Arabidopsis encodes a glutathione S-conjugate
pump: isolation and functional definition of a plant ATP-binding cassette transporter gene.
Proc. Natl. Acad. Sci. USA 1997; 94: 8243-8248.
60. Gao M, Yamazaki M, Loe DW, Westlake CJ, Grant CE, Cole SPC, and Deeley RG. Multidrug
resistance protein. J. Biol. Chem. 1998; 273: 10733-10740.
61. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L,
Borst P, Varadi A, and Sarkadi B. Functional multidrug resistance protein (MRP1) lacking the
N-terminal transmembrane domain. J. Biol. Chem. 1998; 273: 32167-32175.
62. Müller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EGE, and Jansen
PLM. Overexpression of the gene encoding the multidrug resistance-associated protein results
in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA
1994; 91: 13033-13037.
63. Loe DW, Almquist KC, Cole SPC, and Deeley RG. ATP-dependent 17β-estradiol 17-(β-D-
glucuronide) transport by multidrug resistance protein (MRP). J. Biol. Chem. 1996; 271: 9683-
9689.
64. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC, and Deeley RG. Pharmacological
characterization of the murine and human orthologs of multidrug-resistance protein in
transfected human embryonic kidney cells. Mol. Pharmacol. 1997; 52: 344-353.
65. Stride BD, Cole SPC, and Deeley RG. Localization of a substrate specificity domain in the
multidrug resistance protein. J. Biol. Chem. 1999; 274: 22877-22883.
66. Hipfner DR, Mao Q, Qiu W, Leslie EM, Gao M, Deeley RG, and Cole SPC. Monoclonal
antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP.
J. Biol. Chem. 1999; 274: 15420-15426.
67. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D. ATP-dependent transport of
glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994; 54:
4833-4836.
68. Chang X-B, Hou Y-X, and Riordan JR. ATPase activity of purified multidrug resistance-
associated protein. J. Biol. Chem. 1997; 272: 30962-30968.
69. Mao Q, Leslie EM, Deeley RG, and Cole SPC. ATPase activity of purified and reconstituted
multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochim. Biophys. Acta
1999; 1461: 69-82.
70. Hooijberg JH, Pinedo HM, Vrasdonk C, Priebe W, Lankelma J, and Broxterman HJ. The effect
of glutathione on the ATPase activity of MRP1 in its natural membranes. FEBS Lett. 2000;
469: 47-51.
71. Doige CA, Yu X, and Sharom FJ. The effects of lipids and detergents on ATPase-active P-
glycoprotein. Biochim. Biophys. Acta 1993; 1146: 65-72.
72. Gao M, Cui HR, Loe DW, Grant CE, Almquist KC, Cole SPC, and Deeley RG. Comparison of
the functional characteristics of the nucleotide binding domains of multidrug resistance protein
1. J. Biol. Chem. 2000; 275: 13098-13108.
Chapter 1
28
73. Nagata K, Nishitani M, Matsuo M, Kioka N, Amachi T, and Ueda K. Non-equivalent
nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance
protein MRP1. J. Biol. Chem. 2000; 275: 17626-17630.
74. Hou Y-X, Cui L, Riordan JR, and Chang X-B. Allosteric interactions between the two non-
equivalent nucleotide binding domains of multidrug resistance protein MRP1. J. Biol. Chem.
2000; 275: 20280-20287.
75. Chang X-B, Hou Y-X, and Riordan JR. Stimulation of ATPase activity of purified Multidrug
Resistance associated Protein by nucleoside diphosphates. J. Biol. Chem. 1998; 273: 23844-
23848.
76. König J, Nies AT, Cui Y, Leier I, and Keppler D. Conjugate export pumps of the multidrug
resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug
resistance. Biochim. Biophys. Acta 1999; 1461: 377-394.
77. Flens MJ, Zaman GJR, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der
Groep P, de Haas M, Meijer CJLM, and Scheper RJ. Tissue distribution of the multidrug
resistance protein. Am. J. Pathol. 1996; 148: 1237-1247.
78. Müller M, Roelofsen H, and Jansen PLM. Secretion of organic anions by hepatocytes:
involvement of homologues of the multidrug resistance protein. Semin. Liver Dis. 1996; 16:
211-220.
79. Evers R, Cnubben NHP, Wijnholds J, van Deemter L, van Bladeren P, and Borst P. Transport
of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett.
1997; 419: 112-116.
80. Ishikawa T, Akimaru K, Nakanishi M, Tomokiyo K, Furuta K, Suzuki M, and Noyori R. Anti-
cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-
dependent gluathione S-conjugate export pump (GS-X pump). Biochem. J. 1998; 336: 569-576.
81. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SPC, Deeley RG, and Keppler D. ATP-
dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate
export pump. Biochem. J. 1996; 314: 433-437.
82. Hay DW, Torphy TJ, and Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to
new tricks. Trends Pharmacol. Sci. 1995; 16: 304-309.
83. Parker J. Prostaglandin A2 protein interactions and inhibition of cellular proliferation.
Prostaglandins 1995; 50: 359-375.
84. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal,
malondialdehyde and related aldehydes. Free Rad. Biol. Med. 1991; 11: 81-128.
85. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der
Valk M, Krimpenfort P, and Borst P. Increased sensitivity to anticancer drugs and decreased
inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med.
1997; 3: 1275-1279.
86. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, and Borst
P. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular
tubules against drug-induced damage. J. Exp. Med. 1998; 188: 797-808.
87. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, and Piwnica-
Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug
resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability
barrier. Proc. Natl. Acad. Sci. USA 1999; 96: 3900-3905.
88. Nishino J, Suzuki H, Sugiyama D, Kitazawa T, Ito K, Hanano M, and Sugiyama Y.
Transepithelial transport of organic anions across the choroid plexus: possible involvement of
organic anion transporter and multidrug resistance-associated protein. J. Pharmacol. Exp.
Ther. 1999; 290: 289-294.
89. Wijnholds J, de Lange EC, Scheffer GL, van Den Berg DJ, Mol CA, van der Valk M, Schinkel
AH, Scheper RJ, Breimer DD, and Borst P. Multidrug resistance protein 1 protects the choroid
plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 2000;
105: 279-285.
Functions of the MRP-family
29
90. Jansen PLM, Peters WH, and Lamers WH. Hereditary chronic conjugated hyperbilirubinemia
in mutant rats caused by defective hepatic anion transport. Hepatology 1985; 5: 573-579.
91. Mikami T, Nozaki T, Tagaya O, Hosokakwa S, Nakura T, Mori H, and Kondou S. The
characteristics of a new mutant in rats with hyperbilirubinuria syndrome. Congenital Anom.
1986;  26: 250-251.
92. Suzuki H and Sugiyama Y. Excretion of GSSG and glutathione conjugates mediated by MRP1
and cMOAT/MRP2. Semin. Liver Dis.1998; 18: 359-376.
93. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P,
Baas F, and Oude Elferink RP. A mutation in the human canalicular multispecific organic
anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-1542.
94. Paulusma CC, Bosma PJ, Zaman GJR, Bakker CTM, Otter M, Scheffer GL, Scheper RJ,
Borst P, and Oude Elferink RPJ. Congenital jaundice in rats with a mutation in a multidrug
resistance-associated protein gene. Science 1996; 271: 1126-1128.
95. Bakos E, Evers R, Sinko E, Varadi A, Borst P, and Sarkadi B. Interactions of the human
multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 2000;
57: 760-768.
96. Schaub TP, Kartenbeck J, König J, Spring H, Dorsam J, Staehler G, Storkel S, Thon WF, and
Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human kidney
proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 1999; 10: 1159-1169.
97. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, and Sugiyama Y. Involvement of an
organic anion transporter (canalicular multispecific organic anion transporter/multidrug
resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J.
Pharmacol. Exp. Ther. 2000; 292: 433-439.
98. Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, and Sugiyama Y. Function and expression
of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-
2). J. Pharmacol. Exp. Ther. 2000; 292: 265-270.
99. Ullrich KJ and Rumrich G. Luminal transport step of para-aminohippurate (PAH): transport
from PAH-loaded proximal tubular cells into the tubular lumen of the rat kidney in vivo.
Pflugers Arch. 1997; 433: 735-743.
100. Ullrich KJ. Renal transporters for organic anions and organic cations. Structural requirements
for substrates. J. Membr. Biol. 1997; 158: 95-107.
101. Schaub TP, Kartenbeck J, König J, Vogel O, Witzgall R, Kriz W, and Keppler D. Expression
of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney
proximal tubules. J. Am. Soc. Nephrol. 1997; 8: 1213-1221.
102. Leier I, Hummel-Eisenbeiss J, Cui Y, and Keppler D. ATP-dependent para-aminohippurate
transport by apical multidrug resistance protein MRP2. Kidney Int. 2000; 57: 1636-1642.
103. Masereeuw R, Terlouw SA, Van Aubel RA, Russel FG, and Miller DS. Endothelin B receptor-
mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol. Pharmacol.
2000; 57: 59-67.
104. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, and Kondo T. Augmentation of transport
for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res. 1995; 55: 4297-
4301.
105. Ishikawa T, Wright CD, and Ishizuka H. GS-X pump is functionally overexpressed in cis-
diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by
cell differentiation. J. Biol. Chem. 1994; 269: 29085-29093.
106. de Vries EGE, Müller M, Meijer C, Jansen PLM, and Mulder NH. Role of the glutathione S-
conjugate pump in cisplatin resistance. J. Natl. Cancer Inst. 1995; 87: 537-538.
107. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LCJM, Paulusma CC, Oude
Elferink RPJ, Baas F, Schinkel AH, and Borst P. Drug export activity of the human canalicular
multispecific organic anion transporter in polarized kidney MDCK cells expressing
cMOAT(MRP2) cDNA. J. Clin. Invest. 1998; 101: 1310-1319.
Chapter 1
30
108. Cui Y, König J, Buchholz JK, Spring H, Leier I, and Keppler D. Drug resistance and ATP-
dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2,
permanently expressed in human and canine cells. Mol. Pharmacol. 1999; 55: 929-937.
109. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, and Kuwano M. Enhanced
transport of anticancer agents and leukotriene C4 by the human canalicular multispecific
organic anion transporter (cMOAT/MRP2). FEBS Lett. 1999; 456: 327-331.
110. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M,
Kuwano M, and Akiyama SI. Effect of multidrug resistance-reversing agents on transporting
activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 1999;
56: 1219-1228.
111. Borst P, Evers R, Kool M, and Wijnholds J. The multidrug resistance protein family. Biochim.
Biophys. Acta 1999; 1461: 347-357.
112. Van Aubel RA, Koenderink JB, Peters JG, van Os CH, and Russel FG. Mechanisms and
interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit
multidrug resistance protein Mrp2 expressed in insect cells. Mol. Pharmacol. 1999; 56: 714-
719.
113. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, and Borst P.
Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated
with glutathione export. Br. J. Cancer 2000; 83: 375-383.
114. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, and Sugiyama Y. cDNA cloning and inducible
expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998; 433:
149-152.
115. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, and Sugiyama Y. Hepatic
expression of multidrug resistance-associated protein-like proteins maintained in Eisai
hyperbilirubinemic rats. Mol. Pharmacol. 1998; 53: 1068-1075.
116. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree ML, Smith AJ, J ansen G, Peters
GJ, Ponne N, Scheper RJ, Oude Elferink RPJ, Baas F, and Borst P. MRP3, an organic anion
transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA 1999; 96: 6914-
6919.
117. König J, Rost D, Cui Y, and Keppler D. Characterization of the human multidrug resistance
protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999; 29:
1156-1163.
118. Hirohashi T, Suzuki H, Takikawa H, and Sugiyama Y. ATP-dependent transport of bile salts
by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem. 2000; 275: 2905-2910.
119. Stockel B, König J, Nies AT, Cui Y, Brom M, and Keppler D. Characterization of the 5'-
flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in
comparison with the multidrug resistance protein 3 (MRP3) gene. Eur. J. Biochem. 2000; 267:
1347-1358.
120. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M,
and Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol.
Gastrointest. Liver Physiol. 2000; 278: G438-G446.
121. Hirohashi T, Suzuki H, and Sugiyama Y. Characterization of the transport properties of cloned
rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 1999; 274: 15181-15185.
122. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, and Meier
PJ. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian
liver. J. Biol. Chem. 1998; 273: 10046-10050.
123. Kuipers F, Enserink M, Havinga R, van der Steen AB, Hardonk MJ, Fevery J, and Vonk RJ.
Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat.
J. Clin. Invest. 1988; 81: 1593-1599.
124. Müller M and Jansen PLM. The secretory function of the liver: new aspects of hepatobiliary
transport. J. Hepatol. 1998; 28: 344-354.
Functions of the MRP-family
31
125. Zeng H, Bain LJ, Belinsky MG, and Kruh GD. Expression of multidrug resistance protein-3
(multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers
resistance to anticancer agents. Cancer Res. 1999; 59: 5964-5967.
126. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland
A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.
Nat. Med. 1999; 5: 1048-1051.
127. McAleer MA, Breen MA, White NL, and Matthews N. pABC11 (also known as MOAT-C and
MRP5), a member of the ABC family of proteins, has anion transporter activity but does not
confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol.
Chem. 1999; 274: 23541-23548.
128. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper
RJ, Hatse S, De Clercq E, Balzarini J, and Borst P. Multidrug-resistance protein 5 is a
multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad.
Sci. USA 2000; 97: 7476-7481.
129. Jedlitschky G, Burchell B, and Keppler D. The multidrug resistance protein 5 (MRP5)
functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 2000; 275:
30069-30074.
130. Soderling SH and Beavo JA. Regulation of cAMP and cGMP signaling: new
phosphodiesterases and new functions. Curr. Opin. Cell Biol. 2000; 12: 174-179.
131. Martin E, Davis K, Bian K, Lee YC, and Murad F. Cellular signaling with nitric oxide and
cyclic guanosine monophosphate.  Semin. Perinatol. 2000; 24: 2-6.
132. Longhurst TJ, O'Neill GM, Harvie RM, and Davey RA. The anthracycline resistance-
associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia.
Br. J. Cancer 1996; 74: 1331-1335.
133. Madon J, Hagenbuch B, Landmann L, Meier PJ, and Stieger B. Transport function and
hepatocellular localization of mrp6 in rat liver. Mol. Pharmacol. 2000; 57: 634-641.
134. Ringpfeil F, Lebwohl MG, Christiano AM, and Uitto J. Pseudoxanthoma elasticum: Mutations
in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc.
Natl. Acad. Sci. USA 2000; 97: 6001-6006.
135. Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, and Keppler D. The MRP gene
encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
J. Biol. Chem. 1994; 269: 27807-27810.
136. Zaman GJR, Cnubben NH, van Bladeren PJ, Evers R, and Borst P. Transport of the
glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS
Lett. 1996; 391: 126-130.
137. Loe DW, Stewart RK, Massey TE, Deeley RG, and Cole SPC. ATP-dependent transport of
Aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein
(MRP) gene. Mol. Pharmacol. 1997; 51: 1034-1041.
138. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchel B, and Keppler D. ATP-
dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its
hepatic canalicular isofrom MRP2. Biochem. J. 1997; 327: 305-310.
139. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, and Deeley RG.
Overexpression of multidrug resistance-associated protein (MRP) increases resistance to
natural product drugs. Cancer Res. 1994; 54: 357-361.
140. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, and Akiyama SI. ATP-
dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its
inhibition by PAK-104P. Mol. Pharmacol. 1999; 55: 921-928.
141. Feller N, Broxterman HJ, Wahrer DC, and Pinedo HM. ATP-dependent efflux of calcein by the
multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS.
Lett. 1995; 368: 385-388.
142. Keppler D, Cui Y, Konig J, Leier I, and Nies A. Export pumps for anionic conjugates encoded
by MRP genes. Adv. Enzyme Regul. 1999; 39:237-46: 237-246.
Chapter 1
32
143. Dekkers DW, Comfurius P, Schroit AJ, Bevers EM, and Zwaal RF. Transbilayer movement of
NBD-labeled phospholipids in red blood cell membranes: outward-directed transport by the
multidrug resistance protein 1 (MRP1). Biochemistry 1998; 37: 14833-14837.
144. Raggers R, van Helvoort A, Evers R, and van Meer G. The human multidrug resistance protein
MRP1 translocates sphingolipid analogues across the plasma membrane. J. Cell Sci. 1999;
112: 415-422.
145. Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhof R, Borst P, and Oude Elferink RPJ.
Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates
low-affinity transport of reduced glutathione. Biochem. J. 1999; 338: 393-401.
146. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, and Keppler D.
Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat
multidrug resistance protein 2. Hepatology 1999; 30: 485-490.
147. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y. Functional analysis of a
canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem. 1998;
273: 1684-1688.
148. van Aubel RAMH, van Kuijck MA, Koenderink JB, Deen PMT, van Os CH, and Russel FGM.
Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug
resistance-associated protein Mrp2 expressed in insect cells. Mol. Pharmacol. 1998; 53: 1062-
1067.


